Enlivex Therapeutics Ltd. (ENLV)

Enlivex Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	27.32	50.24	11.2	6.84	5.45
Short-Term Investments	0	0	72.93	30.03	8.06
Cash & Cash Equivalents	27.32	50.24	84.13	36.88	13.51
Cash Growth	-45.63%	-40.28%	128.13%	173.01%	38.18%
Other Current Assets	6.44	2.09	2.31	1.24	2.91
Total Current Assets	33.76	52.33	86.44	38.12	16.42
Property, Plant & Equipment	1.54	9.88	2.53	1.48	0.65
Other Long-Term Assets	1.53	5.44	6.17	0.76	0.49
Total Long-Term Assets	3.07	15.31	8.7	2.24	1.14
Total Assets	36.83	67.64	95.15	40.36	17.56
Accounts Payable	0.83	1.95	0.88	0.46	0.32
Current Debt	0	0	0	1.17	3.4
Other Current Liabilities	5.23	4.66	3.84	2.74	2.26
Total Current Liabilities	6.06	6.61	4.72	4.37	5.98
Other Long-Term Liabilities	0.69	4.19	5.39	0.5	0.3
Total Long-Term Liabilities	0.69	4.19	5.39	0.5	0.3
Total Liabilities	6.75	10.8	10.11	4.87	6.28
Total Debt	0	0	0	1.17	3.4
Debt Growth	-	-	-	-65.56%	-
Retained Earnings	-112.09	-83.03	-51.97	-37.5	-25.67
Comprehensive Income	1.1	1.1	1.1	0.98	-1.3
Shareholders' Equity	30.08	56.84	85.04	35.49	11.28
Net Cash / Debt	27.32	50.24	84.13	35.71	10.11
Net Cash / Debt Growth	-45.63%	-40.28%	135.61%	253.25%	3.40%
Net Cash Per Share	1.47	2.73	4.71	2.71	1.17
Working Capital	27.7	45.72	81.72	33.75	10.44
Book Value Per Share	1.62	3.09	4.76	2.69	1.30

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).